BDTX

1.3353.96%
GE

Garry E. Menzel

Independent Director

Dr. Garry E. Menzel, Ph.D., M.B.A. is Operating Partner at GHO Capital Partners LLP since April, 2024. He serves as an Independent Director at Black Diamond Therapeutics, Inc. since March 2017. He serves as Non-Executive Director at Adaptimmune Therapeutics plc since June 1, 2023. He is a co-founder of Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical stage oncology company, where he has served on the Board of Directors since 2014. He served as Independent Director at Stoke Therapeutics, Inc since August 17, 2020 until June 03, 2026. Dr. Menzel joined the Stoke Therapeutics, Inc. in August 2020. He serves as President, Chief Executive Officer and Director of TCR2 Therapeutics Inc. (formerly known as TCR2, Inc.) since 2016. Dr. Menzel served as the Chief Strategy and Financial Officer of Axcella Health, Inc. from July 2015 to September 2016. Dr. Menzel served as Chief Business and Strategy Officer at Axcella Health, Inc. since July 2015 until September 2016. Dr. Menzel served as the Chief Financial Officer of DaVita HealthCare Partners Inc. from September 30, 2013 to May 2015. Dr. Menze served as Senior Vice President of Finance at DaVita HealthCare Partners Inc. from September 16, 2013 to September 30, 2013. He served as the Chief Operating Officer and Executive Vice President of Finance at Regulus Therapeutics Inc. (Regulus Therapeutics, LLC) from 2008 to June 21, 2013. Dr. Menzel served as the Chief Financial Officer of Regulus Therapeutics Inc. Dr. Menzel served as an Executive Vice President of Corporate Development & Finance of Regulus Therapeutics LLC from August 2008 to January 2009. Dr. Menzel served as Senior Vice President and Head of Global Biotechnology Investment Banking of Goldman Sachs, which he joined in 1994 until 2004. He led the IPO and significant strategic partnerships with Astra Zeneca and Sanofi. He was a research assistant at SmithKline Beecham PLC (now GlaxoSmithKline PLC). He served as Global Head of Life Sciences for Credit Suisse. Dr. Menzel served as Consultant of Bain & Company. He served as the Managing Director and Founding Member of the Healthcare Group. Dr. Menzel was employed by Credit Suisse (USA), Inc. and The Goldman Sachs Group, Inc. Dr. Menzel joined Credit Suisse in 2004 and served as its Managing Director until 2008. He served a broad range of biotechnology and pharmaceutical clients around the world, raising capital and negotiating merger agreements for some of its most significant transactions. He served as Director Emeriti of the Institute for Systems Biology. He also had global leadership roles in running the biotechnology practices at Goldman Sachs & Co. LLC and Credit Suisse Group AG, both of which are multinational investment bank and financial services companies, from 1994 to 2004 and from 2004 to 2008, respectively. Dr. Menzel serves on the National Board of the Epilepsy Foundation and the Board of Directors of the University of California, San Francisco (UCSF) School of Pharmacy. Dr. Menzel serves as an Executive Board Member of the Epilepsy Therapy Project. Prior to that, Dr. Menzel served as Chief Operating Officer at microRNA therapy company Regulus Therapeutics, Inc. (Nasdaq: RGLS). He served as a Director of Endeavor Pharmaceuticals Inc., since 2001. He is Associate of the Royal College of Science. Dr. Menzel earned a B.Sc. with honors in Biochemistry from Imperial College of Science & Technology in 1985, a Ph.D. in Biochemistry and Molecular Biology from St. John College, University of Cambridge in 1988 and Master of Business Administration from Stanford University Graduate School of Business in 1994.

Positions